| Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. | |
| | |
MedLine Citation:
|
PMID: 20333419 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Bisphosphonates (BPs) have been widely, efficiently, and safely used for the treatment of osteoporosis, malignant hypercalcemia, bone metastasis of solid cancers, and multiple myeloma bone diseases. Accumulating recent reports describe that surgical dental treatments in patients with cancer or osteoporosis who have been receiving intravenous or oral BPs are associated with osteonecrosis of the jaw (bisphosphonate-related osteonecrosis of the jaw, BRONJ). The accurate incidence, clinical backgrounds, and pathogenesis of BRONJ have been unclear and appropriate approaches for prevention and treatment have not been established to date. To address the current situation of BRONJ in Japan, the "Allied Task Force Committee of Bisphosphonate-Related Osteonecrosis of the Jaw," consisting of physicians specializing in bone biology, orthopedic surgery, rheumatology, obstetrics/gynecology, and medical oncology and dentists specializing in oral surgery, periodontology, dental radiology, and oral pathology, was organized. The committee attempted to propose a standard position paper for the treatment of BRONJ. The committee expects that this proposal will provide objective and correct scientific information on BRONJ and will serve as a reference for conducting dental procedures for patients receiving BPs and in designing prevention and treatment of BRONJ. However, because this position paper is not based on direct clinical evidence, it should be used as a reference, and a decision on treatment in each case should be made after an extensive discussion among physicians, dentists/oral surgeons, and the patients. |
| | |
Authors:
|
Toshiyuki Yoneda; Hiroshi Hagino; Toshitsugu Sugimoto; Hiroaki Ohta; Shunji Takahashi; Satoshi Soen; Akira Taguchi; Satoru Toyosawa; Toshihiko Nagata; Masahiro Urade |
Related Documents
:
|
12058769 - A critical analysis of australian clinical ethics committees and the functions they serve. 18238989 - Acog committee opinion number 397, february 2008: surrogate motherhood. 21283969 - Systemic sclerosis - a systematic overview. 19205659 - Submission of clinical studies to ethics committees or clinical trials registers: the a... 17076129 - Ethics committees in croatia in the healthcare institutions: the first study about thei... 12852119 - Avoiding rejections by european ethics committees. 20944739 - Rise and fall of political complexity in island south-east asia and the pacific. 2040109 - The csci: 'we concentrate on making the grass grow'. 21774599 - From globalization to europeanization-and then? transnational influences in lesbian act... |
Publication Detail:
|
Type: Journal Article Date: 2010-03-24 |
Journal Detail:
|
Title: Journal of bone and mineral metabolism Volume: 28 ISSN: 1435-5604 ISO Abbreviation: J. Bone Miner. Metab. Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-06-28 Completed Date: 2010-09-23 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9436705 Medline TA: J Bone Miner Metab Country: Japan |
Other Details:
|
Languages: eng Pagination: 365-83 Citation Subset: IM |
Affiliation:
|
Department of Biochemistry, Osaka University Graduate School of Dentistry, 1-8 Yamadaoka, Suita, Osaka 565-0871, Japan. tyoneda@dent.osaka-u.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Bone Density Conservation Agents / adverse effects*, therapeutic use Bone Resorption / physiopathology Diphosphonates / adverse effects*, therapeutic use Humans Japan Jaw Diseases / chemically induced*, diagnosis*, drug therapy Models, Biological Osteoclasts / pathology Osteomyelitis / chemically induced, diagnosis Osteonecrosis / chemically induced*, diagnosis* Societies, Medical |
| Chemical | |
Reg. No./Substance:
|
0/Bone Density Conservation Agents; 0/Diphosphonates |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effects of raloxifene treatment on the structural geometry of the proximal femur in Japanese women w...
Next Document: Biological activity of enantiomeric complexes [PtCl(2)L (2)] (L (2) is aromatic bisphosphanes and ar...